CG Oncology, Inc. (CGON)
NASDAQ · Manufacturing · Biological products, (no diagnostic substances)
$67.15−$1.61 (−2.34%) on the dayAs of the close; data may be delayed.
CGON price, last 12 months
Key stats
- Previous close
- $68.76
- Open
- $69.32
- Day range
- $66.76 – $70.05
- 52-week range
- $35.64 – $80.97
- Volume
- 1.2M
- Avg volume (20 days)
- 892.9K
- Market cap
- $6.0B
Performance
1W−10.0%
1M−14.4%
3M−6.7%
6M+0.7%
YTD+61.7%
1Y+83.1%
vs S&P 500, 1Y+66.3 pts
Technicals and fundamentals
About CG Oncology, Inc.
CG Oncology Inc is a late-stage clinical biopharmaceutical company focused on developing and commercializing its product candidate, cretostimogene grenadenorepvec, for patients with bladder cancer. The company's candidate, cretostimogene grenadenorepvec, is a targeted oncolytic intravesically delivered immunotherapy agent that is in two phase three trials (one high-risk BCG unresponsive NMIBC trial and one intermediate-risk NMIBC trial) and a phase two clinical study with a checkpoint inhibitor for high-risk BCG unresponsive NMIBC disease.
- Sector
- Manufacturing
- Industry
- Biological products, (no diagnostic substances)
- Listed on
- NASDAQ
- Market cap
- $6.0B